Relapsed non-Hodgkin's lymphoma: Detection and treatment

Radiation Medicine - Medical Imaging and Radiation Oncology

Volumn 18, Issue 6, 2000, Pages 369-375

  Shioyama, Yoshiyuki ^a   Nakamura, Katsumasa ^b   Kunitake, Naonobu ^b   Kimura, Masahiko ^b   Terashima, Hiromi ^c   Masuda, Kouji ^b  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c KYUSHU UNIVERSITY   (Japan)

Author keywords

Diagnosis; Non Hodgkin's lymphoma; Prognosis; Relapse

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISOLONE; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; PHYSICAL EXAMINATION; SURVIVAL RATE; TIME; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; COMBINED MODALITY THERAPY; FEMALE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; RECURRENCE; RETROSPECTIVE STUDIES; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 0034526615     PISSN: 02882043     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Treatment of refractory and relapsed non-Hodgkin's lymphoma with ifosamide, methotrexate and etoposide
2. Treatment of relapsed non-Hodgkin's lymphoma with a combination of hydroxyurea, ifosamide, and etoposide
3. Effective salvage chemotherapy in relapsed or refractory non-Hodgkin's lymphoma
4. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose ara-C and dexamethasone (DHAP)
5. The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: Analysis of the PARMA trial
6. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma
7. The role of intensive therapy and autologous blood and marrow transplantation for chemotherapy-sensitive relapsed and primary refractory non-Hodgkin's lymphoma: Identification of major prognostic groups
8. Treatment of non-Hodgkin's lymphoma
9. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting
10. Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the parma trial
11. Comparison between conventional salvage therapy and high-dose therapy with autografting for recurrent or refractory Hodgkin's disease
12. Management of recurrent or refractory lymphoma
13. Cost of care and outcomes for high-dose therapy and autologous transplantation for lymphoid malignancies: Results from the University of Nebraska 1987 through 1991
14. The international non-Hodgkin's lymphoma prognostic factors project: A predictive model for aggressive non-Hodgkin's lymphoma
15. Radiotherapy for localized relapse in patients with non-Hodgkin's lymphoma
16. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma
17. Low-grade non-Hodgkin's lymphomas: Report of the Japan Lymphoma Radiation Therapy Group (JLRTG)
18. Results of radiation therapy for extranodal non-Hodgkin's lymphoma in the head and neck: A study of the Japan Lymphoma Radiation Therapy Study Group
19. Results of radiation therapy of stage I non-Hodgkin's lymphoma of Waldeyer's ring
20. Results of radiation therapy for stage I-II non-Hodgkin's lymphoma localized in the head and neck. A report of the Japanese Lymphoma Radiation Therapy Study Group
21. Nodular histiocytic lymphoma, emphasizing results of stage I disease treated by radiotherapy
22. Radiation therapy in the non-Hodgkin's lymphomas
23. Value of follow-up procedures in patients with large-cell lymphoma who achieve a complete remission
24. Patterns of relapse in large-cell lymphoma patients with bulk disease: Implications for the use of adjuvant radiation therapy
25. High serum interleukin-2 receptor levels are related to advanced disease and a poor outcome in childhood non-Hodgkin's lymphoma
26. Soluble interleukin-2 receptor in childhood non-Hodgkin's lymphoma
27. Increased levels of soluble interleukin-2 receptor in non-Hodgkin's lymphomas. Relationship with clinical, histologic, and phenotypic features
28. Whole-body FDG-PET imaging for staging of Hodgkin's disease and lymphoma
29. 18F-FDG to detect residual disease after therapy for malignant lymphoma